This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

DOI 10.1101/2025.04.10.647635

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedFeb 1, 2025

Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition.

Florencia P. Madorsky Rowdo, Rachel N. Martini, Sarah E. Ackermann…·M. Laura Martín

The paper uses CRISPR-Cas9 screens in breast cancer organoids from African ancestry patients to identify essential kinases and show synergy between EGFR and FGFR1 inhibitors.

23 citationstop 3%

humanorganoid / primary culture

𝕏 PostBluesky

Developmental BiologyFrontiers in Cell and Developmental BiologyPeer-reviewedAug 26, 2021

A new pipeline to automatically segment and semi-automatically measure bone length on 3D models obtained by Computed Tomography

Santiago Beltran Diaz, Xinli Qu, Michael Doube…·Alberto Roselló‐Díez

The paper presents a semi-automated pipeline for fast and non-destructive measurement of bone length from micro-CT images of mouse developmental samples.

5 citations

mouseimaging

𝕏 PostBluesky